Macrogenics (MGNX) Tops Q2 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
MacroGenics Provides Update on Corporate Progress and 2nd Quarter 2018 Financial Results
August 7, 2018 4:01 PM EDTROCKVILLE, Md., Aug. 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progress and reported financial results for the quarter ended June 30, 2018.
MacroGenics continues to advance its portfolio of oncology product candidates toward multiple data read-outs, said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. We expect to complete enrollment of the SOPHIA Phase 3 metastatic breast cancer study of margetuximab... More
